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Introduction: The treatment of chronic Pseudomonas aeruginosa infections is challenging, with
resistance and antibiogram diversity accumulating during successive therapies. Some isolates
are resistant to all licensed agents, creating treatment problems and an urgent need for new
therapies. Among antibiotics in advanced development, ceftolozane/tazobactam has potent in
vitro antipseudomonal activity, with low MICs even for strains with AmpC b-lactamase-,
impermeability- and efflux-mediated resistance to other b-lactams.
Case presentation: A bronchiectasis exacerbation in a 59-year-old man involved pan-resistant
P. aeruginosa. Meropenem/colistin therapy failed. Named-patient ceftolozane/tazobactam 2+1 g
every 8 h for 14 days restored baseline respiratory and inflammatory marker status, and the
patient was discharged; the ceftolozane/tazobactam MIC was 8 mg ml21, with most growth
inhibited at 2 mg ml21.
Conclusion: A positive outcome in this difficult infection due to an otherwise pan-resistant P.
aeruginosa is notable, especially as the patient had failed prior therapy with other agents. We
urge formal evaluation of ceftolozane/tazobactam in chronic pseudomonal lung infections.
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Introduction
We present the case report of a 59-year-old man with
chronic bronchiectasis whose pulmonary flora included
Pseudomonas aeruginosa variants that were pan-resistant to
licensed agents, and who failed to improve during therapy
with high-dose meropenem combined with intravenous
(i.v.) and nebulized colistin. Symptoms resolved during
named-patient therapy with ceftolozane/tazobactam, a novel
cephalosporin b-lactamase inhibitor combination, which
was then under regulatory review and has subsequently been
licensed by the US Food and Drug Administration for two
non-pulmonary indications (Anonymous, 2014). Ceftolozane/
tazobactam is notable for in vitro activity againstP. aeruginosa
(Livermore et al., 2009; Shlaes, 2013) and is expected to count
towards the Infectious Disease Society of America’s 106920
Antimicrobial Initiative (Boucher et al., 2013).
Case report
The patient had a long history of respiratory illness. He was
a heavy smoker (30 day21) for almost 30 years but stopped
in 1998. Since 1995, he had been admitted to hospital over
55 times, always for chest infections. He was diagnosed
with bronchiectasis in 1997 and with chronic obstructive
pulmonary disease (COPD) in 2004. Repeated exacerba-
tions of COPD were treated with numerous courses of i.v.
and per os (p.o.) antibiotics as well as steroids. Throughout
2007, he was treated with antibiotics every 5–6 weeks; later
he was prescribed prophylactic doxycycline (100 mg every
24 h) for 1 week every month, aiming to reduce the need
for rescue treatment. From 2009, his chest was colonized
with P. aeruginosa and meticillin-resistant Staphylococcus
Abbreviations: BSAC, British Society for Antimicrobial Chemotherapy;
COPD, chronic obstructive pulmonary disease; EUCAST, European
Committee on Antimicrobial Susceptibility Testing; i.v., intravenous; MIC,
Minimum Inhibitory Concentration; MRSA, meticillin-resistant Staphylo-
coccus aureus; p.o., per os; VNTR, variable number tandem repeat.
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aureus (MRSA) and he was administered long-term
nebulized colistin twice daily thereafter; he also received
long-term oxygen therapy at home. By 2014, his self-
reported exercise tolerance was 100 yards walking when
well. He had received meropenem for 3 weeks around a
month before the episode described here, and multiple
courses of piperacillin/tazobactam (4.5 g every 8 h) around
4 months previously.
In April 2014 (day 0), the patient was admitted as an
emergency case with an exacerbation of bronchiectasis.
Symptoms included increased shortness of breath, increased
oxygen requirement and increasing green sputum produc-
tion. Sputum culture on day 1 grewMRSA and P. aeruginosa
that was pan-resistant to licensed antibiotics, as confirmed by
reference laboratory testing (Table 1). He was given linezolid
600 mg every 12 h p.o. and continued on nebulized colistin
106 U every 12 h. From day 2, the inhaled anti-pseudomonal
therapywas supplementedwithmeropenem2 g every 8 h i.v.
and colistin 26106 U every 8 h i.v., despite in vitro resistance
to both agents. Meropenem infusion times were not
extended. During this treatment, the patient deteriorated
clinically, with white cell counts of 21.66109–26.26109 l21
and C-reactive protein (CRP) of 200–326 mg ml21. His
oxygen requirement rose to 70 % and he produced copious
purulent green sputum. Linezolidwas stopped on day 14, but
the meropenem and i.v. colistin were continued until day 27
when, as there was little else to offer, a palliative care referral
was made. The patient was discharged home, continuing on
the long-term nebulized colistin and oxygen therapies (4 l
min21). He was also given a further course of linezolid
600 mg every 12 h p.o., although there was no recent MRSA
isolate. His condition continued to deteriorate and hewas re-
admitted on day 30 with shortness of breath at rest.
Further reference laboratory testing of the day 0 P.
aeruginosa isolate with unconventional and developmental
agents revealed a ceftolozane/tazobactam MIC of 8+4 mg
ml21 (see below), and the combination was sourced from
Cubist Pharmaceuticals for ‘named-patient’ administra-
tion. Other antibiotics (linezolid, meropenem and colistin)
were stopped and, on day 35, the patient began i.v.
treatment with ceftolozane/tazobactam, 2+1 g every 8 h,
administered as 1 h infusions. At this stage, his white cell
count was 22.66109 l21 and has CRP was 152 mg ml21.
Progressive improvement was achieved during the cefto-
lozane/tazobactam therapy and, by the end of a 14-day
course (day 49), the patient had ceased to produce sputum,
no longer required supplemental oxygen and was breathing
normally on air. His white cell count and CRP returned to
baseline values of 14.76109 l21 and 21 mg ml, respectively.
On day 58, he was discharged on linezolid 600 mg twice a
day for 2 weeks (although, again, there was no recent
MRSA isolate) and continued on long-term nebulized
colistin. He was re-admitted on day 100 and remained in
hospital until day 118 with a further infective exacerbation
of bronchiectasis, for which he was administered mer-
openem 1 g every 8 h and gentamicin 5 mg kg21 every
24 h, and also linezolid following re-isolation of MRSA on
day 105. He was discharged on day 118, again on the
nebulized colistin and with the infection controlled. He
died on day 153.
Microbiological investigations
Susceptibility testing at the local laboratory was by British
Society for Antimicrobial Chemotherapy (BSAC) disc
diffusion (British Society for Antimicrobial Chemotherapy,
2012), whilst P. aeruginosa isolates sent to Public Health
England’s Antimicrobial Resistance andHealthcare Associated
Infections Reference Unit were tested by BSAC agar dilution
(Andrews, 2001)withBSAC/EUCASTbreakpoints (European
Committee on Antimicrobial Susceptibility Testing, 2014).
Ceftolozane and piperacillin were tested with a fixed 4 mg
tazobactam ml21. Referred isolates were fingerprinted by
variable number tandem repeat (VNTR) typing (Turton
et al., 2010).
Local susceptibility results, which spanned exacerbations in
late 2013 as well as the proximate episode, varied over
time, with a trend to increasing resistance and with no
agent retaining consistent activity (Table 1). The day 1
isolate received by the reference laboratory was resistant to
all licensed anti-pseudomonal agents, including merope-
nem and colistin, which the patient was then receiving.
This prompted testing of ceftolozane/tazobactam, where
the MIC was recorded as 8+4 mg ml21, although with the
majority population inhibited at 2+4 mg ml21 with only
isolated colonies growing on the 2 and 4 mg ml21 plates.
Typing revealed that the fully susceptible day 2181 isolate
and the highly resistant day 1 isolates shared the same
VNTR profile (8, 3, 4, 5, 2, 3, 5, 2, 11), implying that a
single infective strain was present, with fluctuating
populations of variably resistant and susceptible variants.
Discussion
This patient, with a long history of pulmonary disease and
treatment, had a complex pulmonary P. aeruginosa flora.
As in cystic fibrosis (Ashish et al., 2013), it is likely that this
variation reflected repeated antibiotic use selecting for
multiple subpopulations of the infective strain in the lung,
varying in resistance but retaining a consistent VNTR type.
The patient’s exacerbation around day 0–1 involved a
variant resistant to all licensed antibiotics and, in keeping
with these in vitro results, he responded poorly to a
meropenem/colistin regimen. Given this therapeutic fail-
ure, we afford little significance to isolating variants on
days 11 and 22 (i.e. during the meropenem/colistin therapy)
that were susceptible to one or both of these agents. This led
to compassionate ‘named-patient’ therapy with ceftolozane/
tazobactam, leading to a considerable clinical improvement.
There were no breakpoints available at the time when this
patient was treated, but the combination has good pene-
tration to the lung (Chandorkar et al., 2012) and the MIC
R. Soliman and others
2 JMM Case Reports
Downloaded from www.sgmjournals.org by
IP:  139.222.81.213
On: Tue, 25 Aug 2015 09:20:03
T
a
b
le
1
.
S
us
ce
p
tib
ili
ty
te
st
in
g
re
su
lts
A
n
ti
b
io
ti
c
P
ri
o
r
ad
m
is
si
o
n
s*
A
d
m
is
si
o
n
d
es
cr
ib
ed
h
er
e
an
d
su
b
se
q
u
en
tl
y
D
ay
2
1
8
1
D
ay
2
1
4
6
D
ay
2
3
3
D
ay
2
2
9
D
ay
2
6
D
ay
1
D
ay
1
1
D
ay
2
2
D
ay
5
2
D
ay
5
6
R
ef
la
b
M
IC
( m
g
m
l2
1
)
L
o
ca
l
L
o
ca
l
L
o
ca
l
L
o
ca
l
R
ef
la
b
M
IC
(m
g
m
l2
1
)
L
o
ca
l
L
o
ca
l
L
o
ca
l
L
o
ca
l
A
m
ik
ac
in
4
(S
)
–
–
–
–
6
4
(R
)
–
–
–
–
G
en
ta
m
ic
in
2
(S
)
S
S
S
S
3
2
(R
)
S
S
S
R
T
o
b
ra
m
yc
in
0
.5
(S
)
–
–
–
–
3
2
(R
)
–
–
–
–
C
ip
ro
fl
o
xa
ci
n
0
.2
5
(S
)
R
R
R
S
.
8
(R
)
R
R
R
R
C
o
li
st
in
2
(S
)
–
S
S
S
.
3
2
(R
)
S
S
R
S
A
zt
re
o
n
am
–
–
–
–
.
6
4
(R
)
–
–
–
–
C
ef
ta
zi
d
im
e
2
(S
)
–
R
R
R
3
2
(R
)
R
R
R
S
Im
ip
en
em
0
.2
5
(S
)
–
–
–
–
6
4
(R
)
–
–
–
–
M
er
o
p
en
em
2
(S
)
–
S
S
R
3
2
(R
)
R
S
R
R
D
o
ri
p
en
em
-
–
–
–
–
8
(R
)
–
–
–
–
C
ar
b
en
ic
il
li
n
6
4
(S
)
–
–
–
–
5
1
2
(R
)
–
–
–
–
P
ip
er
ac
il
li
n
4
(S
)
–
–
–
–
.
6
4
(R
)
–
–
–
–
P
ip
er
ac
il
li
n
/t
az
o
b
ac
ta
m
4
(S
)
S
R
R
R
.
6
4
(R
)
R
R
S
S
C
ef
to
lo
za
n
e/
ta
zo
b
ac
ta
m
–
–
–
–
–
2
–
8
{
–
–
–
–
R
,
re
si
st
an
t;
S
,
su
sc
ep
ti
b
le
.
*C
o
u
n
te
d
fr
o
m
th
e
ad
m
is
si
o
n
d
ay
th
at
le
d
to
ad
m
in
is
tr
at
io
n
o
f
ce
ft
o
lo
za
n
e/
ta
zo
b
ac
ta
m
.
{M
o
st
gr
o
w
th
in
h
ib
it
ed
at
2
m
g
m
l2
1
;
a
fe
w
is
o
la
te
d
co
lo
n
ie
s
o
n
ly
in
h
ib
it
ed
at
8
m
g
m
l2
1
.
B
o
ld
fo
n
t
is
u
se
d
fo
r
re
fe
re
n
ce
la
b
o
ra
to
ry
M
IC
d
at
a
an
d
in
te
rp
re
ta
ti
o
n
.
Successful treatment of ‘pan-resistant’ P. aeruginosa
http://jmmcr.sgmjournals.org 3
Downloaded from www.sgmjournals.org by
IP:  139.222.81.213
On: Tue, 25 Aug 2015 09:20:03
found (8 mg ml21, Table 1) was inferred to predict
susceptibility based on: (i) analogy to ceftazidime, which
has the same maximum dosage and a shorter half-life, with
BSAC/EUCAST breakpoints of: sensitive, #8; resistant,
.8 mg ml21 (European Committee on Antimicrobial
Susceptibility Testing, 2014) and (ii) pharmacodynamic
modelling, indicating 1 log killing up to an MIC of 16 mg
ml21 (Lepak et al., 2014; VanScoy et al., 2014). As the MIC
nevertheless was high compared with typical ceftolozane
values of 0.25–0.5 mg ml21 for P. aeruginosa (Livermore
et al., 2009), a 2+1 g every 8 h regimen was employed, as
presently in phase III trials for ventilator pneumonia,
rather than the 1+0.5 g every 8 h regimen used in phase III
urinary and intra-abdominal trials. The recent US Food
and Drug Authority license for the latter two indications
indicates P. aeruginosa breakpoints of sensitive, #4 mg
ml-1; intermediate, 8 mg ml21; resistant, >16 mg ml-1,
predicated on a 1+0.5 g every 8 h regimen (Anonymous,
2104), and the decision to use the higher-dose regimen is
further justified with reference to these criteria.
In vitro studies show that the MICs of ceftolozane for P.
aeruginosa typically are approximately four- to eightfold
lower than for ceftazidime, which previously was the most
active licensed cephalosporin against this species. MICs of
ceftolozane for P. aeruginosa strains with upregulated efflux
or derepressed AmpC b-lactamase rarely exceed 2–4 mg
ml21, whereas ceftazidime MICs for isolates with these
mechanisms range from 16 to 128 mgml21 (Livermore et al.,
2009; Juan et al., 2010); High-level ceftolozane resistance in
P. aeruginosa appears confined to strains with metallo-
carbapenemases, PER and VEB extended-spectrum b-
lactamases and some cystic fibrosis isolates with complex
mixtures of mechanisms (Livermore et al., 2009; Juan
et al., 2010). Tazobactam protects ceftolozane against the
extended-spectrum b-lactamases of Enterobacteriaceae but
has limited relevance to anti-pseudomonal activity (Shlaes,
2013). Given these data, and assuming regulatory approval,
it seems likely that ceftolozane/tazobactam will often be the
most active agent in vitro against difficult P. aeruginosa
strains from chronic pulmonary infections, including
cystic fibrosis and COPD. We urge that trials should be
done in these settings to validate its therapeutic potential
and to test whether the success described here is
representative.
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